CN110237236A - 用于治疗小阴唇皮肤的皮肤软膏 - Google Patents
用于治疗小阴唇皮肤的皮肤软膏 Download PDFInfo
- Publication number
- CN110237236A CN110237236A CN201910385868.0A CN201910385868A CN110237236A CN 110237236 A CN110237236 A CN 110237236A CN 201910385868 A CN201910385868 A CN 201910385868A CN 110237236 A CN110237236 A CN 110237236A
- Authority
- CN
- China
- Prior art keywords
- skin
- growth factor
- ointments
- treating
- labium minus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002674 ointment Substances 0.000 title claims abstract description 93
- 241000594558 Labium Species 0.000 title claims abstract description 64
- 239000003102 growth factor Substances 0.000 claims abstract description 77
- 239000002131 composite material Substances 0.000 claims abstract description 34
- 229940088597 hormone Drugs 0.000 claims abstract description 20
- 239000005556 hormone Substances 0.000 claims abstract description 20
- 210000004392 genitalia Anatomy 0.000 claims abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 16
- 208000003827 Vulvar Vestibulitis Diseases 0.000 claims abstract description 12
- 239000000470 constituent Substances 0.000 claims abstract description 11
- 239000002552 dosage form Substances 0.000 claims abstract description 11
- 230000003115 biocidal effect Effects 0.000 claims abstract description 7
- 230000007613 environmental effect Effects 0.000 claims abstract description 7
- 239000003270 steroid hormone Substances 0.000 claims abstract description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- 235000004433 Simmondsia californica Nutrition 0.000 claims description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
- MXOAEAUPQDYUQM-QMMMGPOBSA-N (S)-chlorphenesin Chemical compound OC[C@H](O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-QMMMGPOBSA-N 0.000 claims description 7
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 claims description 7
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 claims description 7
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims description 7
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims description 7
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 7
- 241000221095 Simmondsia Species 0.000 claims description 7
- 102000013275 Somatomedins Human genes 0.000 claims description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 7
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 7
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 7
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 7
- 229960003993 chlorphenesin Drugs 0.000 claims description 7
- 229920001577 copolymer Polymers 0.000 claims description 7
- 235000019198 oils Nutrition 0.000 claims description 7
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 7
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 7
- 239000000230 xanthan gum Substances 0.000 claims description 7
- 229920001285 xanthan gum Polymers 0.000 claims description 7
- 229940082509 xanthan gum Drugs 0.000 claims description 7
- 235000010493 xanthan gum Nutrition 0.000 claims description 7
- 108010017843 platelet-derived growth factor A Proteins 0.000 claims description 6
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 6
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 claims description 4
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 239000004310 lactic acid Substances 0.000 claims description 4
- 235000014655 lactic acid Nutrition 0.000 claims description 4
- 239000001331 rosmarinus officinalis leaf Substances 0.000 claims description 4
- 230000001131 transforming effect Effects 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 1
- 101800003838 Epidermal growth factor Proteins 0.000 claims 1
- 229940116977 epidermal growth factor Drugs 0.000 claims 1
- OPCRGEVPIBLWAY-QNRZBPGKSA-N ethyl (2E,4Z)-deca-2,4-dienoate Chemical compound CCCCC\C=C/C=C/C(=O)OCC OPCRGEVPIBLWAY-QNRZBPGKSA-N 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 14
- 230000008929 regeneration Effects 0.000 abstract description 12
- 238000011069 regeneration method Methods 0.000 abstract description 12
- 230000029663 wound healing Effects 0.000 abstract description 6
- 230000010478 bone regeneration Effects 0.000 abstract description 5
- 239000003163 gonadal steroid hormone Substances 0.000 abstract description 4
- 230000000474 nursing effect Effects 0.000 abstract description 4
- 210000003491 skin Anatomy 0.000 description 130
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 238000011084 recovery Methods 0.000 description 12
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 11
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 11
- 229940126864 fibroblast growth factor Drugs 0.000 description 11
- 206010046914 Vaginal infection Diseases 0.000 description 10
- 201000008100 Vaginitis Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 9
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 7
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 7
- 239000003636 conditioned culture medium Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 229920001214 Polysorbate 60 Polymers 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 6
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 6
- 229940113124 polysorbate 60 Drugs 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 206010020880 Hypertrophy Diseases 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000006071 cream Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 208000004746 Atrophic Vaginitis Diseases 0.000 description 3
- 206010003693 Atrophic vulvovaginitis Diseases 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 241001313288 Labia Species 0.000 description 3
- 241001529742 Rosmarinus Species 0.000 description 3
- 241001530490 Salvia rosmarinus Species 0.000 description 3
- 241000221096 Simmondsia chinensis Species 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- FGUZFFWTBWJBIL-XWVZOOPGSA-N [(1r)-1-[(2s,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)O[C@H](CO)[C@H]1OC[C@H](O)[C@H]1O FGUZFFWTBWJBIL-XWVZOOPGSA-N 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 210000003029 clitoris Anatomy 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 230000003054 hormonal effect Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 230000000399 orthopedic effect Effects 0.000 description 3
- 201000010808 postmenopausal atrophic vaginitis Diseases 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 235000015639 rosmarinus officinalis Nutrition 0.000 description 3
- 229940057429 sorbitan isostearate Drugs 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 210000003905 vulva Anatomy 0.000 description 3
- KVZLHPXEUGJPAH-UHFFFAOYSA-N 2-oxidanylpropanoic acid Chemical compound CC(O)C(O)=O.CC(O)C(O)=O KVZLHPXEUGJPAH-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000005864 Sulphur Substances 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000002281 colonystimulating effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000003953 foreskin Anatomy 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000036560 skin regeneration Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 206010056651 Vestibulitis Diseases 0.000 description 1
- 206010047786 Vulvovaginal discomfort Diseases 0.000 description 1
- 206010069055 Vulvovaginal pain Diseases 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000004999 sex organ Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/196—Thrombopoietin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2046—IL-7
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2053—IL-8
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明涉及一种用于治疗小阴唇皮肤的皮肤软膏,更具体来说,其构成上的特征为,作为皮肤软膏,含有复合生长因子(Multi Growth Factor)作为活性成分。根据本发明提出的用于治疗小阴唇皮肤的皮肤软膏,作为皮肤软膏,含有复合生长因子作为活性成分,周期性地被涂抹到用户外阴部,可使生长因子诱导用户皮肤的再生,从而提高外阴前庭炎或小阴唇手术引起的伤口治疗效果,并解决其根本性原因。另外,根据本发明的皮肤软膏既含有高浓度的复合生长因子,又以软膏的剂型制备,容易施用于外阴部,其构成排除了性激素、环境激素、类固醇激素及抗生素成分,不会破坏用户激素均衡,孕产妇或哺乳妇女也可以安心使用。
Description
技术领域
本发明涉及一种皮肤软膏,更具体来说涉及一种用于治疗小阴唇皮肤的皮肤软膏{SKIN OINTMENT FOR TREATING SKIN OF THE LABIA MINORA}。
背景技术
小阴唇是指在女性生殖器官中的外生殖器中位于大阴唇内侧的薄皮肤,小阴唇过大或非对称时,会给日常生活带来不便,在夏天或温度较高的环境下,细菌或霉菌的增殖比一般人多,因此,阴道炎、外阴前庭炎发生率更高。为了消除这种生活上的不便,有些情况下,可进行小阴唇手术。除了出于治疗目的的手术,近年来也有出于美容目的进行小阴唇手术的情况。
图1是用于说明小阴唇肥大症手术的倾向的示意图。通过图1可以确认,对小阴唇进行激光手术后,进行再手术的比例较高。从进行小阴唇形态对称或缩小手术后再手术比例较高的这一点来说,可以知道对小阴唇手术的满意度较低,且小阴唇手术后的管理也非常重要。若小阴唇手术后,没有进行恰当的管理,可能导致小阴唇皮肤疾病或因周围发生干燥症而产生不便。因此为了术后管理和快速恢复,实际上已将软膏作为处方,用于小阴唇手术后帮助小阴唇的皮肤恢复。此时,涂抹于小阴唇手术部位的软膏,大多数使用与用于阴道炎治疗的软膏相同的软膏。
阴道炎是女性常有的疾病,其症状为,阴道分泌物过多,阴道分泌物有恶臭,带下症也可以被看作是阴道炎的症状。发生阴道炎的原因,有细菌性感染,即维持阴道内酸性的乳酸菌减少从而引起细菌增殖;此外,也有由于激素的不均衡或免疫系统或新陈代谢不顺畅导致的非感染性阴道炎。现代社会,由于压力或过度减肥等导致免疫力下降的情况较多,不仅年纪较大的女性,年纪较轻的女性的阴道炎发生率也呈上升趋势。此外,阴道干燥症作为女性疾病的一种,是由于阴道内粘膜层的水分减少,阴道壁变薄而发生的疾病,通常,对此类疾病也使用激素软膏作为治疗剂。阴道干燥症,在2000年初还是40、50岁以上女性患者才有的症状,但由于过度减肥等引起的免疫力下降,现在10几岁,20几岁的患者也在增多,对该疾病的关注度也越来越高。
如上所述,医院在大部分情况下,将激素软膏等作为解决方法提供给患者,用于小阴唇手术后恢复、阴道炎、阴道干燥症等治疗,实际处方中有含有雌性激素、类固醇等的软膏。与此相关的现行技术有,注册专利第10-0400411号(发明名称:阴道炎治疗用生菌制剂)
然而,这些激素软膏存在一些问题,即效果是暂时的或症状几乎没有得到改善。另外,若中断涂抹,有时症状又会重新出现。由于怀疑这是对软膏产生中毒症状,不仅是患者,甚至医生也越来愈顾虑使用含有激素或类固醇的制剂。另外,雌性激素的治疗制剂存在的最大的问题是增加女性癌症的发病率,对于年轻女性,还存在由于发生激素不均衡引起的副作用的事例。由于这些问题,需要开发一种不含激素且对症状的治疗效果较好的软膏。
发明内容
【技术课题】
本发明为了解决传统方法中存在的上述问题而提出,其目的是提供一种用于治疗小阴唇皮肤的皮肤软膏,作为皮肤软膏,含有复合生长因子(Multi Growth Factor)作为活性成分,周期性地被涂抹到用户外阴部,可使生长因子诱导用户皮肤的再生,从而提高外阴前庭炎或小阴唇手术引起的伤口治疗效果,并解决其根本性原因。
另外,本发明的另一个目的为提供一种用于治疗小阴唇皮肤的皮肤软膏,该皮肤软膏既含有高浓度的复合生长因子,又以软膏的剂型制备,容易施用于外阴部,其构成排除了性激素、环境激素、类固醇激素及抗生素成分,不会破坏用户激素均衡,孕产妇或哺乳妇女也可以安心使用。
【技术解决方法】
为了达到所述目的,基于本发明的特征的用于治疗小阴唇皮肤的皮肤软膏,其构成上的特征为,作为皮肤软膏,含有复合生长因子(Multi Growth Factor)作为活性成分。
优选地,周期性地被涂抹到用户外阴部,用来治疗外阴前庭炎或小阴唇手术引起的伤口。
优选地,所述复合生长因子,可以是包含成纤维细胞生长因子(FGF)、碱性成纤维细胞生长因子(bGFG)、粒细胞-巨噬细胞集落刺激生长因子(GM-CSF)、肝细胞生长因子(HGF)、胰岛素样生长因子1(IGF-1)、白细胞介素-6、7、8(IL-6、7、8)、角质细胞生长因子(KGF)、基质蛋白(Matrix poteins)、血小板衍生生长因子AA(PDGF-AA)、转化生长因子β2(TGF-B2)、转化生长因子β3(TGF-B3)、表皮生长因子(EGF)、血管内皮生长因子(VEGF)及肿瘤坏死因子(TNF)的复合生长因子。
优选地,以重量为基准,可以以200,000ppm~400,000ppm的浓度含有所述复合生长因子。
更优选地,以重量为基准,可以以300,000ppm的浓度含有所述复合生长因子。
更优选地,可以包含精制水、甘油(glycerin)、霍霍巴籽油(Simmondsiachinensis(jojoba)seed oil)、黄原胶(Xanthan gum)、丙烯酸羟乙酯/丙烯酰二甲基牛磺酸钠共聚物(hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer)、角鲨烷(squalane)、聚山梨酯60(polysorbate 60)、迷迭香叶油(Rosmarinus officinalis(Rosemary)leaf oil)、乳酸(lactic acid)、氯苯甘醚(Chlorphenesin)及山梨坦异硬脂酸酯(Sorbitan isostearate),并以软膏剂型制备。
更优选地,可以排除雌性激素、环境激素、类固醇激素及抗生素成分。
【发明的效果】
根据本发明提出的用于治疗小阴唇皮肤的皮肤软膏,作为皮肤软膏,含有复合生长因子(Multi Growth Factor)作为活性成分,周期性地被涂抹到用户外阴部,可使生长因子诱导用户皮肤的再生,从而提高外阴前庭炎或小阴唇手术引起的伤口治疗效果,并解决其根本性原因。
另外,根据本发明的皮肤软膏既含有高浓度的复合生长因子,又以软膏的剂型制备,容易施用于外阴部,其构成排除了性激素、环境激素、类固醇激素及抗生素成分,不会破坏用户激素均衡,孕产妇或哺乳妇女也可以安心使用。
附图说明
图1是用于说明小阴唇肥大症手术的倾向的示意图;
图2是用于说明生长因子效能的示意图;
图3是示出根据本发明一个实施例的用于治疗小阴唇皮肤的皮肤软膏的成分的示意图;
图4是给接受小阴唇及阴蒂整形术的患者涂抹根据本发明一个实施例的用于治疗小阴唇皮肤的皮肤软膏后,观察到的恢复程度的照片;
图5是给因小阴唇肥大而及接受手术的患者涂抹根据本发明一个实施例的用于治疗小阴唇皮肤的皮肤软膏后,观察到的恢复程度的照片;
图6是给被诊断为外阴前庭炎及萎缩性阴道炎的患者涂抹根据本发明一个实施例的用于治疗小阴唇皮肤的皮肤软膏后,观察到的恢复程度的照片。
具体实施方式
为了帮助本发明技术领域具有一般知识的人容易理解本发明,下面将参照示意图,详细说明本发明的优选实施例。然而,在详细说明本发明优选实施例时,发明者认为相关的已知功能或构成要素的具体说明会使本发明的主旨模糊,这些详细说明将被省略。同时,对于起到类似的功能及作用的部分,在整个示意图中都使用同一符号。
另外,在整个说明书中,一个部分与另一个部分“连接”不仅包括“直接连接”的情况,也包括两者中间夹着另一元素的“间接连接”的情况。另外,“包含”一种构成要素,若没有特别相反的记载,并不代表不包含其他构成要素,而是指可能还包含其他构成要素。
根根据本发明的一个实施例的用于治疗小阴唇皮肤的皮肤软膏,其构成上的特征为,作为皮肤软膏,含有复合生长因子(Multi Growth Factor)作为活性成分。以往为了治疗小阴唇皮肤,使用了用于阴道炎等的产品,但这些产品没有利用生长因子,从这点上,作为本发明,用于治疗小阴唇皮肤的皮肤软膏利用生长因子尤其复合生长因子,由此具有诱导再生功能,与传统的软膏有着明显的差异。尤其是,本发明不是暂时缓解疼痛,而是再生皮肤组织和阴道粘膜层,从而解决根本性的症状发生原因,本发明在这点上具有意义。
图2是用于说明生长因子效能的示意图。如图2所示,生长因子与细胞受体结合,促进细胞的生长、增殖及分化,起到使用户皮肤自然的再生周期更加顺畅进行。即生长因子起到增加皮肤的胶原蛋白和弹性蛋白的量并使皮肤再生的作用,而女性的小阴唇也由胶原蛋白构成,因此可以通过生长因子使细胞的再生周期顺畅进行,最终可以解决根本性原因。
在本发明中,生长因子被用户小阴唇皮肤吸收,诱导用户皮肤细胞的再生,可以是包含成纤维细胞生长因子(FGF)、碱性成纤维细胞生长因子(bGFG)、粒细胞-巨噬细胞集落刺激生长因子(GM-CSF)、肝细胞生长因子(HGF)、胰岛素样生长因子1(IGF-1)、白细胞介素-6、7、8(IL-6、7、8)、角质细胞生长因子(KGF)、基质蛋白(Matrix poteins)、血小板衍生生长因子AA(PDGF-AA)、转化生长因子β2(TGF-B2)、转化生长因子β3(TGF-B3)、表皮生长因子(EGF)、血管内皮生长因子(VEGF)及肿瘤坏死因子(TNF)的复合生长因子。尤其是根根据本发明的一个实施例的用于治疗小阴唇皮肤的皮肤软膏,不是单独使用表皮生长因子(EGF)或成纤维细胞生长因子(FGF),而是以多肽链因子(Multi peptide factor)的蛋白质形态含有上述所列多个生长因子。
各个生长因子具有不同的功能,例如,表皮生长因子(EGF)为上皮细胞生长因子,可以促进上皮细胞的生长;成纤维细胞生长因子(FGF)是可以刺激成纤维细胞生长的生长因子,具有强化伤口治愈能力和促进皮肤再生的功能,促使胶原蛋白的分泌使其参与皮肤组织的再构建。另外,血小板衍生生长因子(PDGF)刺激血管生成,促进伤口组织的消除和治愈,角质细胞生长因子(KGF)刺激血管生成细胞的分裂和分化,提高单核细胞和巨噬细胞的功能,促进表皮细胞的增殖。由于人体细胞不是仅由一种细胞构成,而根据本发明的一个实施例的用于治疗小阴唇皮肤的皮肤软膏包含复合生长因子,可利用各种生长因子帮助各种细胞的增殖和再生,由此可以得到更快的再生速度和效果。
为了对小阴唇皮肤进行治疗,在相应部位的皮肤上涂抹含有复合生长因子的、根据本发明的一个实施例的用于治疗小阴唇皮肤的皮肤软膏,可使复合生长因子渗透到用户皮肤中,改善小阴唇皮肤疾病,并提高治疗效果。生长因子具有没有免疫排斥反应,也没有副作用的优点。
根据本发明的一个实施例的用于治疗小阴唇皮肤的皮肤软膏,以重量为基准,可以以200,000ppm~400,000ppm的浓度含有所述复合生长因子,更具体地,以重量为基准,可以以300,000ppm的浓度含有所述复合生长因子。根据本发明的一个实施例的用于治疗小阴唇皮肤的皮肤软膏所含有的复合生长因子,为20%~40%的高浓度生长因子条件培养液,优选30%的高浓度生长因子条件培养液,根据实施例,30%的高浓度生长因子条件培养液还可以与天然营养成分及保湿成分混合配制。
传统的包含生长因子的皮肤用产品,大部分含量在1,000ppm以下,不会另外公开浓度,不公开浓度是出于浓度较低,因此即使以2,000ppm的浓度,也可以与传统皮肤用产品产生差别化。根据本发明的一个实施例的用于治疗小阴唇皮肤的皮肤软膏,含有200,000ppm~400,000ppm的高浓度的复合生长因子,含有传统皮肤用产品中含有的生长因子的10~20倍的生长因子,由于这个差异,在皮肤改善及治疗效果上,与低浓度的产品存在显著差异。
尤其,根据本发明的一个实施例的用于治疗小阴唇皮肤的皮肤软膏,利用生长因子条件培养液(Conditioned Media),生成最适合于人体皮肤和组织的生长因子,可以使小阴唇皮肤组织及细胞膜再生效果极大化。即,若将冷冻粉末形态即冷冻后粉碎的粉末形态的生长因子配制到产品中时,不仅很难准确设定其含量,而且由于生长因子本身是蛋白质,将其冷冻时,其效果与蛋白质形态相比显著(80~90%以上)下降。但根据本发明的一个实施例的用于治疗小阴唇皮肤的皮肤软膏,使用维持原有蛋白质形态的生长因子条件培养液,与使用冷冻粉末形态的生长因子相比,可以取得显著优秀的效果。
同时,根据本发明的一个实施例的用于治疗小阴唇皮肤的皮肤软膏,其构成不含有雌性激素、环境激素、类固醇激素及抗生素成分,孕产妇及哺乳妇女也可以放心使用,根据实施例,还可以包括维生素、氨基酸、透明质酸中至少一种以上。
图3是示出根据本发明一个实施例的用于治疗小阴唇皮肤的皮肤软膏的成分的示意图。如图3所示,本发明一个实施例的用于治疗小阴唇皮肤的皮肤软膏包括30%重量比的复合生长因子,还包含精制水、甘油(glycerin)、霍霍巴籽油(Simmondsiachinensis(jojoba)seed oil)、黄原胶(Xanthan gum)、丙烯酸羟乙酯/丙烯酰二甲基牛磺酸钠共聚物(hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer)、角鲨烷(squalane)、聚山梨酯60(polysorbate 60)、迷迭香叶油(Rosmarinus officinalis(Rosemary)leaf oil)、乳酸(lactic acid)、氯苯甘醚(Chlorphenesin)及山梨坦异硬脂酸酯(Sorbitanisostearate),并以软膏剂型制备。
含有生长因子的传统皮肤用制品,大部分为安瓶(ampoule)形态或稀薄的乳霜形态。尤其,若以高浓度含有生长因子,被制备为半固体外用制剂即软膏的剂型存在较大困难。然而,根据本发明一个实施例的用于治疗小阴唇皮肤的皮肤软膏,含有如图3所示的成分,从而不仅含有300,000ppm的高浓度的复合生长因子,还被制备为软膏剂型,其粘性和触感与安瓶及乳霜不同,容易涂抹在小阴唇皮肤上。尤其是,若采用稀薄的制品,用户不容易将其直接涂抹在小阴唇皮肤上,且由于穿着内衣和身体活动等原因,复合生长因子无法通过外阴部皮肤充分被吸收。由此,根据本发明一个实施例的用于治疗小阴唇皮肤的皮肤软膏,被制备为含有高浓度复合生长因子的半固体皮肤软膏剂型,容易涂抹于小阴唇皮肤上,使高浓度的复合生长因子充分被皮肤吸收,从而对外阴前庭炎或小阴唇手术引起的伤口治疗具有显著效果。
[实施例1]
从位于加利福尼亚尔湾分校的组织银行(Tissue Bank at University ofCalifornia,Irvine)获得的人体成纤维细胞(从包皮(foreskin)中提取)中,筛选健康存活的成纤维细胞,在所有培养过程中维持一致的生长因子浓度,以条件培养液(conditionedmedia)形态制备复合生长因子。制备的复合生长因子,包括成纤维细胞生长因子(FGF)、碱性成纤维细胞生长因子(bGFG)、粒细胞-巨噬细胞集落刺激生长因子(GM-CSF)、肝细胞生长因子(HGF)、胰岛素样生长因子1(IGF-1)、白细胞介素-6、7、8(IL-6、7、8)、角质细胞生长因子(KGF)、基质蛋白(Matrix poteins)、血小板衍生生长因子AA(PDGF-AA)、转化生长因子β2(TGF-B2)、转化生长因子β3(TGF-B3)、表皮生长因子(EGF)、血管内皮生长因子(VEGF)及肿瘤坏死因子(TNF)。混合复合生长因子、精制水、甘油(glycerin)、霍霍巴籽油(Simmondsiachinensis(jojoba)seed oil)、黄原胶(Xanthan gum)、丙烯酸羟乙酯/丙烯酰二甲基牛磺酸钠共聚物(hydroxyethylacrylate/sodium acryloyldimethyl taurate copolymer)、角鲨烷(squalane)、聚山梨酯60(polysorbate 60)、迷迭香叶油(Rosmarinus officinalis(Rosemary)leaf oil)、乳酸(lactic acid、氯苯甘醚(Chlorphenesin)及山梨坦异硬脂酸酯(Sorbitan isostearate),并制备软膏剂型的用于治疗小阴唇皮肤的皮肤软膏,使其以重量为基准,含有300,000ppm浓度的复合生长因子。将已制备皮肤软膏放入15ml容量的管状容器。
[实验例1]
给接受小阴唇及阴蒂整形术的女性提供已制备的、放入15ml容量的管状容器的用于治疗小阴唇皮肤的皮肤软膏,让患者周期性地在外阴部上每天涂抹1次,手术后经过2周的观察。
图4是给接受小阴唇及阴蒂整形术的患者涂抹根据本发明一个实施例的用于治疗小阴唇皮肤的皮肤软膏后,观察到的恢复程度的照片,(a)是手术前,(b)是手术后经过2周后的照片。在手术部位即右侧小阴唇部位周期性地每天涂抹1次本发明的用于治疗小阴唇皮肤的皮肤软膏,结果可以确认,在经过2周后得到明显恢复。
[实验例2]
给因小阴唇肥大而及接受手术的女性提供已制备的、放入15ml容量的管状容器的用于治疗小阴唇皮肤的皮肤软膏,让患者周期性地在外阴部上每天涂抹1次,手术后经过20天的观察。
图5是给因小阴唇肥大而及接受手术的患者涂抹根据本发明一个实施例的用于治疗小阴唇皮肤的皮肤软膏后,观察到的恢复程度的照片。上端是手术前状态,下端的(a)是手术后4天,(b)是手术后1周,(c)是手术后经过19天后的照片。图5的(a)、(b)及(c)中,左侧小阴唇为被涂抹了在小阴唇手术后常规处方的含有激素的软膏后逐步呈现出的恢复程度(照片中用“OINT”表示),左侧小阴唇为被涂抹了本发明的用于治疗小阴唇皮肤的皮肤软膏后逐步呈现出的恢复程度(照片中用“WMPF”表示)。从图5的(a)、(b)及(c)中可以确认,涂抹了本发明的用于治疗小阴唇皮肤的皮肤软膏的部位的皮肤,与涂抹一般软膏的部位相比,再生进行更快,其形态的恢复也更好。因此,本发明的用于治疗小阴唇皮肤的皮肤软膏,与传统软膏相比,对小阴唇手术引起的伤口治疗具有更显著的效果,对形态修复也更有帮助,从而可以提高小阴唇手术的满意度。
[实验例3]
给被诊断为外阴前庭炎及萎缩性阴道炎的女性提供已制备的、放入15ml容量的管状容器的用于治疗小阴唇皮肤的皮肤软膏,让患者周期性地在外阴部上每天涂抹1次,手术后经过48天的观察。
图6是给被诊断为外阴前庭炎及萎缩性阴道炎的患者涂抹根据本发明一个实施例的用于治疗小阴唇皮肤的皮肤软膏后,观察到的恢复程度的照片。图6的上端是施用根据本发明一个实施例的用于治疗小阴唇皮肤的皮肤软膏之前的照片,显示出一位患者的外阴部,该患者从10年前起由于外阴疼痛、性交痛、骨盆痛、下腹痛、腰痛及外阴不适、尿痛、尿频、夜尿、尿急等排尿症状,日常生活感到较多不便。所述患者被诊断为外阴前庭炎及萎缩性阴道炎后,进行了3次左后的激素疗法,但仍未看到治疗效果。在所述患者的外阴部周期性地每天涂抹1次根据本发明一个实施例的用于治疗小阴唇皮肤的皮肤软膏后,观察外阴部的恢复程度。
图6下端的(a)是施用本发明的皮肤软膏17天,(b)是施用本发明的皮肤软膏27天,(c)是施用本发明的皮肤软膏48天后的照片。具体来看,可以从图6上端的照片中可以确认,在涂抹根据本发明一个实施例的用于治疗小阴唇皮肤的皮肤软膏前,外阴部肿起严重,并伴有出血症状,而周期性涂抹根据本发明一个实施例的用于治疗小阴唇皮肤的皮肤软膏后,通过图6的(a)至(c)可以确认,外阴部的出血已止,恢复到本来外阴部的颜色。不仅如此,通过图6可以确认,即使在通过传统激素疗法等治疗无法取得治疗效果的情况下,仍可通过根据本发明一个实施例的用于治疗小阴唇皮肤的皮肤软膏,对外阴前庭炎等小阴唇皮肤疾病取得明显的治疗效果。
根据本发明中提出的用于治疗小阴唇皮肤的皮肤软膏,作为皮肤软膏,含有复合生长因子(Multi Growth Factor)作为活性成分,周期性地被涂抹到用户外阴部,可使生长因子诱导用户皮肤的再生,从而提高外阴前庭炎或小阴唇手术引起的伤口治疗效果,并解决其根本性原因。
另外,根据本发明的皮肤软膏,既含有高浓度的复合生长因子,又以软膏的剂型制备,容易施用于外阴部,其构成排除了性激素、环境激素、类固醇激素及抗生素成分,不会破坏用户激素均衡,孕产妇或哺乳妇女也可以安心使用。
如上所述的本发明,可以由在本发明所属领域具有一般知识的人进行多种修改或应用。本发明的技术思想范围应通过以下权利请求范围来确定。
Claims (7)
1.一种用于治疗小阴唇皮肤的皮肤软膏,其特征为,作为皮肤软膏,含有复合生长因子作为活性成分。
2.根据权利请求第1项所述的用于治疗小阴唇皮肤的皮肤软膏,其特征为,周期性地涂抹于用户外阴部,用来治疗外阴前庭炎或小阴唇手术引起的伤口。
3.根据权利请求第1项所述的用于治疗小阴唇皮肤的皮肤软膏,其特征为,所述复合生长因子,是包含成纤维细胞生长因子、碱性成纤维细胞生长因子、粒细胞-巨噬细胞集落刺激生长因子、肝细胞生长因子、胰岛素样生长因子1、白细胞介素-6、7、8、角质细胞生长因子、基质蛋白、血小板衍生生长因子AA、转化生长因子β2、转化生长因子β3、表皮生长因子、血管内皮生长因子及肿瘤坏死因子的复合生长因子。
4.根据权利请求第1项所述的用于治疗小阴唇皮肤的皮肤软膏,其特征为,以重量为基准,以200,000ppm~400,000ppm的浓度含有所述复合生长因子。
5.根据权利请求第4项所述的用于治疗小阴唇皮肤的皮肤软膏,其特征为,以重量为基准,以300,000ppm的浓度含有所述复合生长因子。
6.根据权利请求第4项所述的用于治疗小阴唇皮肤的皮肤软膏,其特征为,还包含精制水、甘油、霍霍巴籽油、黄原胶、丙烯酸羟乙酯/丙烯酰二甲基牛磺酸钠共聚物、角鲨烷、聚山梨酯60、迷迭香叶油、乳酸、氯苯甘醚及山梨坦异硬脂酸酯,并以软膏剂型制备。
7.根据权利请求第1项所述的用于治疗小阴唇皮肤的皮肤软膏,其特征为,不含有雌性激素、环境激素、类固醇激素及抗生素成分。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180086840A KR101924894B1 (ko) | 2018-07-25 | 2018-07-25 | 소음순 피부 치료용 피부연고 |
KR1020180086840 | 2018-07-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110237236A true CN110237236A (zh) | 2019-09-17 |
Family
ID=64668960
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910385868.0A Pending CN110237236A (zh) | 2018-07-25 | 2019-05-09 | 用于治疗小阴唇皮肤的皮肤软膏 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20210046161A1 (zh) |
JP (1) | JP7410574B2 (zh) |
KR (1) | KR101924894B1 (zh) |
CN (1) | CN110237236A (zh) |
WO (1) | WO2020022627A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101924894B1 (ko) * | 2018-07-25 | 2018-12-04 | 베네브바이오랩 주식회사 | 소음순 피부 치료용 피부연고 |
KR102579844B1 (ko) * | 2022-10-18 | 2023-09-19 | 비엔뷔바이오랩 주식회사 | 인체 조직 재생 효과가 있는 인체 섬유아세포 배양액 복합물(g4prf-300), 이의 제조 방법 및 이를 포함하는 피부 외용 액상 조성물 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1160582A (zh) * | 1996-12-27 | 1997-10-01 | 暨南大学生物工程研究所 | 含有细胞生长因子的皮肤外用组合物 |
CN101884602A (zh) * | 2010-03-03 | 2010-11-17 | 孙杰 | 一种皮肤美容修复抗衰除皱的化妆品制剂 |
CN102811704A (zh) * | 2010-01-06 | 2012-12-05 | 奥夫莱夫塔埃克尼公司 | 稳定化的植物来源的生长因子在皮肤护理中的使用方法 |
CN103182070A (zh) * | 2013-04-12 | 2013-07-03 | 江苏迪沃生物制品有限公司 | 一种外用组合物、制剂及其应用 |
CN104056258A (zh) * | 2014-06-05 | 2014-09-24 | 武汉科隆生物医学有限公司 | 促进受损组织生理调节性再生的组合物及制备方法与应用 |
US20150023908A1 (en) * | 2011-03-04 | 2015-01-22 | Ahmed H. Al-Qahtani | Skin cream |
CN106075399A (zh) * | 2016-07-22 | 2016-11-09 | 简婷婷 | 用于激素性皮炎的组合物,制剂及制备方法和应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060058238A1 (en) * | 2004-09-15 | 2006-03-16 | Lee Laurent-Applegate | Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same |
EP2088895B1 (en) * | 2006-12-11 | 2016-07-20 | The Procter and Gamble Company | Single-use personal care products and kits comprising same |
EP2680865B1 (en) * | 2011-03-04 | 2017-04-26 | Al-Qahtani, Ahmed H. | Skin cream |
JP6326601B2 (ja) | 2013-03-13 | 2018-05-23 | アンティース ソシエテ アノニム | 皮膚更新のためのペプチド及び前記ペプチドを使用する方法 |
KR102564239B1 (ko) * | 2014-12-03 | 2023-08-09 | 마리 케이 인코포레이티드 | 화장료 조성물 및 이를 이용하는 방법 |
ITUB20155902A1 (it) * | 2015-11-25 | 2017-05-25 | Nathura S P A | Composizione farmaceutica cicatrizzante per uso topico |
KR101924894B1 (ko) * | 2018-07-25 | 2018-12-04 | 베네브바이오랩 주식회사 | 소음순 피부 치료용 피부연고 |
-
2018
- 2018-07-25 KR KR1020180086840A patent/KR101924894B1/ko active IP Right Grant
-
2019
- 2019-05-09 CN CN201910385868.0A patent/CN110237236A/zh active Pending
- 2019-05-21 US US17/051,165 patent/US20210046161A1/en active Pending
- 2019-05-21 JP JP2020560469A patent/JP7410574B2/ja active Active
- 2019-05-21 WO PCT/KR2019/006065 patent/WO2020022627A1/ko active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1160582A (zh) * | 1996-12-27 | 1997-10-01 | 暨南大学生物工程研究所 | 含有细胞生长因子的皮肤外用组合物 |
CN102811704A (zh) * | 2010-01-06 | 2012-12-05 | 奥夫莱夫塔埃克尼公司 | 稳定化的植物来源的生长因子在皮肤护理中的使用方法 |
CN101884602A (zh) * | 2010-03-03 | 2010-11-17 | 孙杰 | 一种皮肤美容修复抗衰除皱的化妆品制剂 |
US20150023908A1 (en) * | 2011-03-04 | 2015-01-22 | Ahmed H. Al-Qahtani | Skin cream |
CN103182070A (zh) * | 2013-04-12 | 2013-07-03 | 江苏迪沃生物制品有限公司 | 一种外用组合物、制剂及其应用 |
CN104056258A (zh) * | 2014-06-05 | 2014-09-24 | 武汉科隆生物医学有限公司 | 促进受损组织生理调节性再生的组合物及制备方法与应用 |
CN106075399A (zh) * | 2016-07-22 | 2016-11-09 | 简婷婷 | 用于激素性皮炎的组合物,制剂及制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
JP2021533081A (ja) | 2021-12-02 |
US20210046161A1 (en) | 2021-02-18 |
JP7410574B2 (ja) | 2024-01-10 |
WO2020022627A8 (ko) | 2020-10-29 |
KR101924894B1 (ko) | 2018-12-04 |
WO2020022627A1 (ko) | 2020-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bellini et al. | A journey through liposuction and liposculture | |
Kim et al. | Rejuvenation using platelet-rich plasma and lipofilling for vaginal atrophy and lichen sclerosus | |
Panfilov | Augmentative phalloplasty | |
CN101209267B (zh) | 红色诺卡氏菌细胞壁骨架在制备治疗皮肤损伤和疮疡的药物中的用途 | |
Xu | Burns regenerative medicine and therapy | |
CN110237236A (zh) | 用于治疗小阴唇皮肤的皮肤软膏 | |
Castro-Núñez | Distraction sugosteogenesis: its biologic bases and therapeutic principles | |
CN101926872A (zh) | 治疗糖尿病足溃疡的中药解毒生肌膏及其制备方法 | |
Teng et al. | The modified McIndoe technique: a scar-free surgical approach for vaginoplasty with an autologous micromucosa graft | |
CN110522716A (zh) | 一种治疗子宫脱垂的阴道注入剂及其制备方法 | |
CN106822318A (zh) | 治疗老年性阴道炎的外用药剂及其制备方法 | |
CN114259555B (zh) | 一种中西医结合复合制剂及其应用 | |
CN102357263A (zh) | 一种可用于美容和美体的促自体外周前体脂肪细胞增殖和增大的复合诱导剂及其制备方法 | |
Burt | Thick split-skin graft for anal stenosis, Paget's disease, condyloma acuminata, pruritus ani and other anorectal conditions: Report of four cases | |
CN105168625B (zh) | 一种临床护理上用于治疗二、三期褥疮的中药涂膜剂 | |
Chama et al. | A RANDOMISED CONTROL CLINICAL STUDY TO EVALUATE THE EFFECT OF NALPAMARA YASTIMADHU OINTMENT APPLICATION ON EPISIOTOMY WOUND. | |
RU2113183C1 (ru) | Способ лечения бактериального вагиноза | |
Davison et al. | Labiaplasty and labia minora reduction | |
Suvarna | Clinical Study on Efficacy of Tumbi-Lodhra Ointment in Episiotomy Wound | |
CN101485738A (zh) | 治疗阴道炎的栓剂及其制备方法与使用方法 | |
Htinashyal | A Clinical Study of Effects of Chaturbeeja Churna in Sutika Paricharya Wsr Katishoola | |
CN105250711A (zh) | 一种治疗剖宫产术后腹部切口硬结的中药组合物 | |
KR20220105717A (ko) | 질 내 수용성 겔 조성물 | |
Miao et al. | Research Progress of Traditional Chinese and Western Medicine Dressing Change on Wound Healing After Anal Fistula Surgery | |
Mugadur | Comparative study of jatyadi taila and daruharidra rasakriya in the management of dustha vrana |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |